Cell and Gene Therapy Supply Chain Market From Niche to Mainstream Securing the Future of Medicine 2024-2031

Cell and Gene Therapy Supply Chain/Logistics Market to Record An Exponential CAGR By 2031

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Cell and Gene Therapy Supply Chain/Logistics Market (By Application area (Donor eligibility assessment, Sample collection, Manufacturing, Logistics, Patient verification and treatment follow-up), By Type of software solution (Cell orchestration platform, Enterprise manufacturing system,

Inventory management system, Laboratory information management system, Logistics management system, Patient management system, Quality management system, Tracking and tracing system), By Mode of Deployment (Cloud-based solution, On-premises solution), By End-user (Biobank, Cell therapy lab, Hospital, Research institute, Commercial organization)), By Region, Trends, Industry Competition Analysis, Revenue and Forecast Till 2031"

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1694

Cell and Gene Therapy Supply Chain Market Poised for Significant Growth
The cell and gene therapy supply chain/logistics market is on track for a significant leap, with projections estimating a rise from US$1.23 billion in 2022 to US$3.12 billion by 2031 (InsightAce Analytic). This translates to a promising Compound Annual Growth Rate (CAGR) of 11.2% from 2024 to 2031, reflecting the exciting potential of this sector.

Customized Solutions Drive Growth
A key driver of this growth is the ability of cell and gene therapy supply chain management services to provide customizable solutions across various stages. This flexibility caters to the personalized care needs of this field and ensures the safe and efficient transportation of these delicate therapies.

Technology as a Key Enabler
The complex and demanding nature of cell and gene therapy supply chains necessitates advanced IT solutions. Pharmaceutical companies are increasingly partnering with IT providers to automate and streamline processes.

These cutting-edge supply chain information control systems allow for real-time monitoring, management, and manipulation of data with just a few clicks. Companies like Marken, for example, are developing technologies specifically designed to handle the intricate logistics of the rapidly growing gene and cell therapy industry.

The Future is Bright
The ongoing advancements in supply chain management solutions, coupled with the increasing demand for cell and gene therapies, are expected to propel significant market growth in the coming years. This market holds immense promise for revolutionizing healthcare by ensuring the safe and efficient delivery of these life-changing therapies.

The growing need for cell and gene treatments, growing medical trials, and improvements in real-time supply chain operations are expected to enhance the quality of the supply chain management services during the forecast period. In addition, developing medical technologies, rising customizable facilities, enhancing efficacy of CGT supply chain services, and the increasing innovations in the supply services fuel the market expansion. However, the excessive funding cost required for CGT supply chain services, lack of standard therapy protocols, and complicated tactics may hamper the market growth over the projected period.

In terms of region, the North America region is the primary revenue holder of this market due to rising awareness about cell therapies, increasing government investments in the R&D of cell therapies to treat various diseases and high demand for novel therapies. In addition to this, the Asia-Pacific market is expected to grow faster owing to the growing cell therapy manufacturing industries and the improving efficiency of CGT supply chain services.

Request for ToC/Proposal:
Some of the key players in the Cell and Gene Therapy Supply Chain/Logistics market are Be The Match BioTherapies, MAK-SYSTEM, Cryoport, Brooks Life Sciences, Lykan Bioscience, Clarkston Consulting, SAP, Hypertrust Patient Data Care, Haemonetics, MasterControl, TraceLink, SAVSU Technologies, TrakCel, Title21 Health Solutions, sedApta Group, Vineti, Stafa Cellular Therapy, Thermo Fisher Scientific(Patheon), McKesson, Biocair, Marken(UPS Company), Modality Solutions, Almac, Arvato Supply Chain Solutions SE, Catalent, Inc, BioLife Solutions, Inc, Biostor Ltd, Yourway Biopharma Services Company, Atelerix Ltd and Other Prominent Players.

Leading manufacturers of this field focus on offering high quality and customizable services to the clients. Also, partnerships, collaborations, mergers, and acquisitions are helping market players to boost their businesses.

Key developments in the market:
In Jan 2023, Cryoport and Syneos Health formed a new strategic partnership to improve cell and gene therapies. The partnership will help cell and gene therapies get better around the world and will be the first fully integrated biopharmaceutical and supply chain solution for the business. This agreement will help speed up treatment and improve results by giving more people around the world access to these life-changing therapies.

In Oct 2022, TrakCel and ZS collaborated to advance cell and gene orchestration using AI-based solutions. The objective of the TrakCel and ZS partnership was to contribute proactive analysis and forecasting to reduce further treatment delays, product loss, and resource waste, thereby reducing the global cost of CGTs.

The partnership aimed to extend supply chain orchestration beyond the visibility of supply chain progress into end-to-end order orchestration implementation and the ability to take immediate action to the planning to modify and improve the supply chain in order to increase efficiencies and decrease delivery times and costs.

In March 2021, Be The Match BioTherapies and Orchard Therapeutics had expanded their multi-year partnership to include supply chain services in support of the upcoming commercial launch of LibmeldyTM (autologous CD34+ cells encoding the ARSA gene), Orchard's recently approved gene therapy in Europe for the treatment of early-onset metachromatic leukodystrophy. (MLD).

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1694

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Application Area
• Donor eligibility assessment
• Sample collection
• Manufacturing
• Logistics
• Patient verification and treatment follow-up

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Software Solution
• Cell orchestration platform
• Enterprise manufacturing system
• Inventory management system
• Laboratory information management system
• Logistics management system
• Patient management system
• Quality management system
• Tracking and tracing system

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on End-User
• Biobank
• Cell Therapy Lab
• Hospital
• Research Institute
• Commercial Organization

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Deployment
• Cloud-Based
• On-premises

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada

Europe Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2023 to 2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2023 to 2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2023 to 2031
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2023 to 2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for global Cell and Gene Therapy Supply Chain/Logistics market
 To receive industry overview and future trends of global Cell and Gene Therapy Supply Chain/Logistics market
 To analyze the Cell and Gene Therapy Supply Chain/Logistics market drivers and challenges
 To get information on the Cell and Gene Therapy Supply Chain/Logistics market size value (US$ Mn) forecast till 2031
 Major Investments, Mergers & Acquisition in global Cell and Gene Therapy Supply Chain/Logistics market industry

For More Information @ https://www.insightaceanalytic.com/report/cell-and-gene-therapy-supply-chain-logistics-market/1694

Contact US:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.